A venture capital firm based in Taipei, Taiwan solely invests in early stage medical technology ventures. The firm currently manages a Medtech Fund which was raised in 2012 and closed at USD 100 million. The firm focuses on Series A and B rounds and looks to allocate USD 500K to 3 million per round with reserved follow-on investments. The firm will target companies in Taiwan, Israel, and the US. The firm is actively seeking new investments.

The firm looks to invest in innovative medical devices. The firm seeks breakthrough products that are clearly differentiated and superior to existing products. The firm is opportunistic in terms of subsectors and will consider devices in Class I, II, and III. The firm is indication agnostic but only seeks large market opportunities of at least $500 million in targeted annual revenue.

The firm seeks a strong and experienced management team and typically seeks board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Dublin, Ireland has approximately €100M AUM and focuses solely on the life sciences. The firm has 2 funds and plans to raise a third fund in the near future. The firm typically allocates between €5-7M of equity over the life of the investment. The firm primarily invests in companies that are based in Ireland and Europe. Exceptional opportunities in North America will also be considered. The firm is actively seeking new investment opportunities.

The firm invests in biotech therapeutic and diagnostic and medical device companies. For biotech, the firm prefers to invest in companies with first/best-in-class products in or nearing phase I, but will also consider phase II and outstanding companies in pre-clinical. For medical devices, the firm prefers companies with advanced prototype products or with initial clinical of concept completed. The firm is agnostic in terms of subsectors and indications, including orphan indications, but is very interested in products that address clear unmet opportunities. Historically, the firm invested in biotech therapeutics that addresses inflammatory, oncology, respiratory, autoimmune, and cardiovascular disorders. Medical devices: therapeutic for cardiovascular diseases, non-active implantable device for pulmonary embolism, renal and vascular diseases.

The firm requests a board seat in each portfolio company. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An evergreen life science venture fund located in Europe was established in 2009 and wholly owned by a strategic foundation. The fund’s evergreen structure allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. The fund has an annual investment capacity of approximately €50m. Investments are typically above €10-35m, and the firm prefers to take above 10% ownership. The fund is looking to invest primarily in Europe and in the USA/Canada.

The fund invests exclusively in life sciences, focusing on pharmaceuticals and medtech. For therapeutics, the firm typically prefers to invest at phase I/II but has also made investments at earlier phases of development. The fund will consider investing in medtech companies at the commercialization stage. The firm is open to opportunities in all therapeutic areas and indications.

The fund is oriented towards opportunities in the US and Europe and will take the role of lead investor in Europe. In US/Canada the firm prefers to syndicate with well-established VC investors specialized in life sciences. The fund expects to be actively in communication with management and represented on the supervisory board of portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm founded in 2001 and headquartered in San Francisco California recently closed its 3rd fund at $310 million. The firm makes growth equity investments ranging from approximately $15 to $40 million over the investment’s lifetime. The firm primarily invests within the United States but is open to consider international investment as well.

The firm is currently looking for commercial stage companies in areas of medical technology and devices, life science instruments and tools, healthcare IT, healthcare services, agriculture and animal health. The firm is agnostic in terms of therapeutic indication.

The firm only invests in companies with commercial revenue. The firm supports organic growth strategies, which allow for gross profit growth and investment in product pipelines and commercial expansion. The firm looks to take a seat on the company board and prefers to be the lead or sole institutional investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture fund of a multinational healthcare company has allocated CHF 500 million to invest in and develop commercially successful innovative life science companies. The fund is an evergreen fund and makes equity investment in early-stage biotech therapeutic and diagnostic companies. The fund prefers Series A. The typical initial investment size ranges from CHF 1-5M with capital reserved for follow-on financing. The fund invests in companies that are based in Europe, North America, and the Pacific Region. The fund is actively seeking new investment opportunities.

The Fund is looking to invest in companies with innovative new technologies, medicines or diagnostics, particularly in the areas of interest to the fund’s parent company. This includes: Oncology, Central Nervous System, Inflammation, Anti-Infectives, Virology, in-Vitro Diagnostics, Diabetes Care, and Molecular Diagnostics. For therapeutic biotech, the fund is willing to invest in companies that are still 18-24 months away from the clinic. The fund highly prefers companies with both a discovery engine and a product pipeline.

The Fund invests in private and public companies. The fund only invests in public companies as part of a collaboration entered into by the parent company’s pharma or diagnostics division. The fund requests board seats and typically prefers to be in an ownership range of 15% or more. In general, the fund prefers to co-invest with leading venture funds as well as other corporate venture funds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm with offices throughout Europe, The US and the Middle East has approximately €540M AUM and is currently managing five active funds. The firm’s fifth fund had its first close at €92M in October 2014, with the aim to raise €150-200M. The firm makes equity investment in life sciences and biomedical technology companies at all stages of development. However, the firm prefers late stage preclinical or early stage clinical for therapeutics and diagnostics and medical devices that are close to market approval. The typical investment per round is €3M to €7M. The firm looks for companies that are based in the US, Canada, Israel, and Europe. The firm is actively screening new investment opportunities.

The firm is generally opportunistic in the life sciences space. The firm targets therapeutics and diagnostics, medical devices, and biopharmaceuticals. In therapeutics, the firm focuses on drug development and is open to all indications including orphan indications. In medical devices, the firm has a special focus on interventional devices in cardiology, gastroenterology and pulmonology that are close to or on the market approval. However, the firm is equally opportunistic in other subsectors and indications for medical devices, but all with a therapeutic focus.

The firm invests in companies at all stages of their development. For drug development, the firm invests from late preclinical to mid-stage clinical development. The firm sometimes considers companies with products on the market. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital branch of a drug retailing chain looks to make strategic equity investments into companies of up to $5 million. The firm is generally stage agnostic although they prefer companies at or near commercialization. The firm is actively reviewing new investment opportunities and is open to consider companies from around the globe.

The firm is focused on investing in companies of mutual strategic benefit to the parent company. This includes companies in sectors of Medical Devices, Point of Care Diagnostics, Healthcare Services, Pharmacy Innovation, and Sensors/Wearable devices. For medical devices and diagnostics the company prefers products that are near or have reached commercialization as the firm can add significant strategic value in distribution, marketing and sales. The firm is also very interested in products that will be sold directly to patients or devices/diagnostics that will be able to be used in the firms clinics. For wearable devices and sensors the firm is most interest in technologies with clinical value in terms of disease treatment and/or management.  The firm is open to all indication types.

The firm is looking for privately held companies with experienced management teams. The firm looks to take a board observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com